Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
Status:
Unknown status
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This study will test the ability of an immune modulator, anti-OX40 (MEDI6469) to alter the
immune cell environment within colorectal cancer metastases. The drug will be administered to
patients before surgical treatment.